A Comparative Clinical Trial of Efonidipine and Amlodipine in Management of Stage-I Hypertension: A Randomized, Double-Blind Study in Indian Population
Journal of Advances in Medicine and Medical Research · pp. 1–12 · Published 13 Jan 2018
10.9734/JAMMR/2018/38509Abstract
Aims: The present clinical study was conducted to establish non-inferiority of efonidipine hydrochloride ethanolate (efonidipine) as compared to amlodipine besylate (amlodipine) in the management of Stage-I hypertension. Study Design: The study was a prospective, cohort, double-blind, double-dummy, randomized phase-III clinical trial Place and Duration of Study: Nine geographically distributed sites across India were involved in the clinical trial between January 2015 to June 2016. Background: The use of conventional L-type CCBs is often limited due to associated side effects. Efonidipine, a dual T- and L-type Ca2+ channel blocker has been proven to exhibit antihypertensive effect along with renoprotective actions with minimum systemic side effects. The present clinical study was conducted to evaluate the safety and efficacy of efonidipine for the first time in Indian patients with Stage-I hypertension. Methodology: The present phase-III clinical trial was a double-blind, double-dummy, multi-center, and parallel group study conducted on the Indian population. A total of 200 patients were randomized to receive either efonidipine 40 mg (n=95) or amlodipine 5 mg (n=105) once daily for 28 days. The patients were evaluated for changes in the systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. Results: Efonidipine reduced SBP by 18.2 ± 12.2 mmHg, DBP by 10.7 ± 7.0 mmHg and heart rate was diminished by 8.1 ± 8.3 bpm while amlodipine reduced SBP by 19.2 ± 11.8 mmHg, DBP by 10.2 ± 7.7 mmHg and heart rate by 7.2 ± 9.9 bpm. Conclusion: Efonidipine was concluded to be non-inferior to amlodipine in the reduction of SBD, DBP, and heart rate and was found to be comparable to amlodipine in the management of hypertension and its safety profile. Clinical Trial Registration: The trial was registered with the Clinical Trial Registry of India; Reg. No: CTRI/2015/01/005359; Available at: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=7747&EncHid=&userName=CTRI/2015/01/005359
Cited by 1
Suresh Davis, Anu R. Raju, Eapen Thomas · Journal of Cardiovascular Pharmacology · 2019
Related research
- Dietary Pattern and Prevalence of High Blood Pressure among Adult Traders in Port Harcourt, Nigeria — shares topic coverage
- Impact of the Diet Profile and Alcohol Consumption on Cardiometabolic Risks in Dschang Health District-Cameroon — shares topic coverage
- Gender Specific Predictive Performance and Optimal Threshold of Anthropometric Indices for the Prediction of Hypertension among a Ghanaian Population in Kumasi — shares topic coverage
- Metabolic Syndrome and Kidney Damage: Prevalence and Assessment of Risk among Apparently Healthy Resident of Ado Ekiti, South West Nigeria — shares topic coverage
- Analysis of Risk Factors among Diabetic Patients Visiting Diabetic Research Clinic at Nishtar Hospital Multan-Pakistan — shares topic coverage
Article metrics
Real usage data collected on this platform.
36
Page views
0
PDF downloads
4
Outbound clicks
1
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.